Drug Risk-Adjusted Net Present Value
Access the risk-adjusted Net Present Value (NPV) of a specific drug.
Reveal a combination of analytics and proprietary data to deliver a complete picture of a drug’s current valuation based on revenue, R&D, likelihood of approval and sales-related costs.
This data will enable you to make better-informed decisions on the investment potential of a drug.
Included in these reports:
- Current investment value of a drug based on multiple factors, including LoA, revenue and sales-related costs
- Outlines key future events that could impact a drug’s NPV
We are the trusted, gold standard intelligence provider to the world’s largest industries
GlobalData powers faster, more informed decisions with:
- Granular industry intelligence: We develop deep, vertical-specific intelligence tailored to your industry, providing 360° insight.
- Exhaustive coverage: We synthesize our vast data universe into formats that support your decision-making needs, covering the sectors, themes, companies and geographies that matter to you.
- Proprietary datasets: We provide you with access to untapped pools of intelligence generated from our proprietary datasets and primary research capabilities.
- Robust methodologies: The quality and timeliness of our data is a key differentiator. We leverage robust research methodologies to turn millions of data points into trusted intelligence
Thousands of companies, government organizations, and decision makers rely on GlobalData
We have a track record of serving truly diverse clients, including:
- Corporates: From refining strategy to fostering innovation, our insights power decisions for all corporate functions.
- Investment firms: From balancing risks to identifying alpha signals, our insights are widely used by investors and financial analysts.
- Professional services: We give consultants, legal, and accounting firms the critical insights to make faster, more informed decisions.
- Other sectors: From media to academia, we work with sectors as diverse as our data.
The trusted, actionable and future-proof insight you need to stay ahead
We have decades of experience in being the gold standard intelligence provider based on:
- Unique data: Our proprietary data sources are unmatched and untapped, giving you exclusive insights to drive decisions.
- Expert analysis: Leverage collective expertise. Count on our extensive team of researchers, analysts, subject matter experts, and journalists, plus thousands of external thought-leaders.
- Real intelligence over AI: Experience a level of analysis that leaves AI in the dust. Unlock the proprietary datasets unseen by AI and gain a decisive edge.
- Time-saving research solutions: Save hundreds of hours on research. Our comprehensive reports let you focus on delivering actionable insights - not searching for them.
- Unparalleled global coverage: Tap into insights from anywhere. Our extensive global coverage offers an unrivalled view of the market landscape.
- One platform: Access all our unique data, expert analysis, and innovative solutions on one platform.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Ruzotolimod
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Ruzotolimod report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Regeneron Pharmaceuticals Inc’s Fianlimab
Empower your strategies with our Net Present Value Model: Regeneron Pharmaceuticals Inc's Fianlimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: MeiraGTx Holdings Plc’s AAV-GAD
Empower your strategies with our Net Present Value Model: MeiraGTx Holdings Plc's AAV-GAD report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Pfizer Inc’s Sisunatovir Hydrochloride
Empower your strategies with our Net Present Value Model: Pfizer Inc's Sisunatovir Hydrochloride report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Fortress Biotech Inc’s Olafertinib
Empower your strategies with our Net Present Value Model: Fortress Biotech Inc's Olafertinib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Pfizer Inc’s PF-06425090
Empower your strategies with our Net Present Value Model: Pfizer Inc's PF-06425090 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Ipatasertib
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Ipatasertib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Pfizer Inc’s Inclacumab
Empower your strategies with our Net Present Value Model: Pfizer Inc's Inclacumab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AbbVie Inc’s ABBV-668
Empower your strategies with our Net Present Value Model: AbbVie Inc's ABBV-668 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: GSK plc’s GSK-4178116A
Empower your strategies with our Net Present Value Model: GSK plc's GSK-4178116A report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.